A Phase III, Open Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3).
- Spencer, Andrew (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research